Barely Significant
← all excerpts

Long-term outcome of neoadjuvant tislelizumab plus chemotherapy in locally advanced esophageal squamous cell carcinoma.

Cancer Immunol Immunother · 2025 · PMC12715071 · PMID 41410741

Europe PMCDOI
3
hedged sentences
0.1880
closest p · 3.8× alpha
0.1880
boldest claim

The sentences

did not reach statistical significancep = 0.188not close (p > 0.1)
In contrast, among patients without MPR, adjuvant therapy showed a trend toward better DFS, although this did not reach statistical significance ( p = 0.188).

also in 57,071 other papers

showed a trendp = 0.188not close (p > 0.1)
In contrast, among patients without MPR, adjuvant therapy showed a trend toward better DFS, although this did not reach statistical significance ( p = 0.188).

also in 24,539 other papers

an encouraging trendno p-value reported
Our study revealed an encouraging trend in both DFS and OS within the adjuvant treatment cohort, during the early stage, which persisted throughout the observation period.

also in 160 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.